CytrRx Corporation traded at $0.12 this Monday February 6th, increasing $0.04 or 41.18 percent since the previous trading session. Looking back, over the last four weeks, CytrRx Corporation gained 13.61 percent. Over the last 12 months, its price fell by 74.75 percent. Looking ahead, we forecast CytrRx Corporation to be priced at 0.08 by the end of this quarter and at 0.07 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 4,182.00 11.00 0.26% 19.55%
Brainstorm Cell Therapeutics 2.31 -0.39 -14.44% -29.57%
Bioline Rx 0.61 -0.01 -0.89% -65.81%
Celldex Therapeutics 46.14 0.05 0.11% 46.94%
Curis 0.76 -0.02 -2.46% -77.36%
CytrRx Corporation 0.12 0.04 41.18% -74.75%
Glaxosmithkline 35.81 0.47 1.33% -20.40%
J&J 161.90 -1.46 -0.89% -5.60%
Karyopharm Therapeutics 3.37 -0.03 -0.88% -67.09%
Novartis 85.61 0.14 0.16% -1.83%
Northwest Biotherapeutics 0.74 0.02 3.35% -18.50%
Roche Holding 285.00 1.10 0.39% -17.61%
Seattle Genetics 136.00 -2.00 -1.45% -3.40%

Indexes Price Day Year
USND 11884 -3.48 -0.03% -16.28%
US2000 1946 -11.26 -0.58% -4.84%

CytrRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology and rare diseases. The Company is focused on the discovery, research and clinical development of anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The Company's Linker Activated Drug Release (LADR) technology platform is a discovery engine to create a pipeline of anti-cancer molecules that avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. Its product candidate, Aldoxorubicin is a rationally engineered cytotoxic which delivers anti-cancer agent, doxorubicin, into the tumor is in late-stage clinical trials. Its other product candidate, Arimoclomol is also in clinical trials for Niemann Pick disease Type C (NPC) and Gaucher disease through Orphazyme A/S.